AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01628705 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Nutritional intervention
Description: The subjects were undergoing nutritional intervention was reduced by 500 kcal per day of habitual caloric intake.~The proportion of daily intake of macronutrient in the moderate-fat diet was: 30% fat (saturated fat \<7%, monounsaturated 10-15% and polyunsaturated 10%, respectively to total calories), 15% of protein, and 55% of carbohydrates. The dietary cholesterol was less than 200 mg/day, fiber intake was increased to 25 grams per day (50% soluble fiber).
Study NCT01628705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: The patients drank secha green tea. Subjects of the INT group were instructed on how to prepare the green tea infusion. Each cup was prepared using 3g of dried green tea in 300ml of hot water (temperature 80°C)for 4 min. It was drunk fresh and without sugar. The treatment consisted of 2 cup/day of green tea, one in the morning and one at night. The amount of epigallocathechin-3-gallate was 498mg/day.
Study NCT03431766 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: On control group A once the dental implants are inserted on both mandible or maxilla of the patient placebo (group A) would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
Study NCT03431766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.20% chlorhexidine gel
Description: On test group B once the dental implants are inserted on both mandible or maxilla of the patient a 0.20% chlorhexidine gel would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
Study NCT03029442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (Prolia)
Description: In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates. The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
Study NCT03029442 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Identical Denosumab volume of normal saline
Study NCT02853539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Subcutaneous injection of Denosumab
Study NCT02848404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Categorical Language Fluency Smartphone Application
Description: 4 weeks' training
Study NCT00190450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft intracerebral of foetal neurons
Description: graft intracerebral of foetal neurons
Study NCT03902301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus group
Description: Nutrition intervention focused on the treatment of insulin resistance + Lactobacillus rhamnosus supplementation (6x10 9 of lactobacillus rhamnosus x 2 times a day) (35 people).
Study NCT03902301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary group
Description: Nutritional intervention focused on the treatment of insulin resistance (35 subjects).
Study NCT02596633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-support Acceptance and Commitment Therapy (ACT)
Description: Telephone-support Acceptance and Commitment Therapy (ACT): ACT self-help book and 8 telephone support calls
Study NCT01989676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280014
Description: Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the PF-05280014 regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
Study NCT01989676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
Study NCT01989676 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin®
Description: Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion weekly until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the Herceptin® regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
Study NCT01989676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
Study NCT00354562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-751
Description: 200mg ABT-751 daily for 14 days every 21 days
Study NCT00354562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 14 days every 21 days
Study NCT00354562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Standard Docetaxel every 21 days
Study NCT00354562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Standard Docetaxel every 21 days
Study NCT01275716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications
Description: Subjects will be randomly assigned (like the flip of a coin) to a study group. One group will be given before and after treatment pictures of their affected heart arteries. The other group will not be shown these pictures. Both groups will still receive written and verbal information about living a heart healthy lifestyle and taking heart medications properly as part of their normal routine care.
Study NCT04688372 — intervention group
Intervention type: OTHER
Intervention: Surge Index
Description: See study description above
Study NCT01114581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucinex
Description: Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study
Study NCT01114581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given as 2 tablets
Study NCT00537017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 5 mg BID capsules
Study NCT00537017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
Study NCT00537017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Parkinson's Disease treatments
Description: Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O methyl transferase (COMT) inhibitor entacapone.
Study NCT03436953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-8998
Description: T-type calcium channel blocker
Study NCT01197664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: Given PO
Study NCT01197664 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT01197664 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT01197664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01197664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01197664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given PO
Study NCT01197664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given PO
Study NCT01722123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothetical scenarios and related decisions
Description: Patients are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
Study NCT00066638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given IV
Study NCT00066638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01685866 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vein-Viewer Vision
Description: A medical device called Vein-Viewer Vision
Study NCT01814384 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: prosthesis GMK ® without the ancillary MyKnee ® LBS
Study NCT01814384 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Matched patient cutting blocks MyKnee ® LBS
Study NCT03484377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: The experimental condition will use a constant current of 2mA for 20 minutes, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
Study NCT03484377 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The anodal electrode will be placed over the supreorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The session will last for 20 minutes.
Study NCT01805440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Uridine
Description: Uridine is the active treatment in this clinical trial.
Study NCT01805440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill placebo is the inactive treatment comparator in this clinical trial.
Study NCT00993902 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intrauterine insemination (single)
Description: Single IUI after 36-38 hours of HCG
Study NCT00993902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double intrauterine insemination
Description: Double insemination after 18 and 40 hours of HCG administration.
Study NCT02095223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyographic Biofeedback
Description: Electromyographic biofeedback is a device that enables a patient or clinician to measure the intensity of a muscle contraction using electrodes placed on the skin over a muscle of interest. In this study, participants in the electromyographic biofeedback supplemented exercise will also be instructed on correct setup and use of the electromyographic biofeedback unit. These instructions will focus on correct placement of the electromyographic recording electrodes over quadriceps muscle as well as correct tuning of the feedback threshold for each exercise to maximize the benefit of the intervention. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group.
Study NCT02095223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Exercise
Description: All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
Study NCT02095223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Exercise
Description: All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
Study NCT00509041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: 50 mg PO bid
Study NCT01907997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic intravenous lidocaine infusion
Description: In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
Study NCT01907997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline infusion
Description: In group C, the patients receive same volume of normal saline
Study NCT03484637 — intervention group
Intervention type: OTHER
Intervention: Lifestyle-medicine intervention
Study NCT03926871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic Training
Description: The ergonomic training consisted of an educational program in Ergonomics with a duration of 60 (sixty) minutes divided into a theoretical exposition and videos of the occupational tasks performed by the workers themselves. Theoretical lecture covered topics such as ergonomics, human anatomy, worker health, prevention measures to minimize the risks of musculoskeletal diseases. A better way of performing the work to protect the musculoskeletal system was demonstrated.
Study NCT01858376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Capros dietary supplement
Description: Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.
Study NCT01391754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare
Description: Behavioral home based family preservation. Weekly visits X six months.
Study NCT01391754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vivo coached quality control
Description: Live observation of practice with expert coaching, feedback and fidelity monitoring
Study NCT01391754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services As Usual
Description: Home based services not using the SafeCare model
Study NCT01391754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services As Usual
Description: Home based services not using the SafeCare model
Study NCT01391754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uncoached
Description: No in vivo coached quality control or fidelity monitoring
Study NCT01391754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uncoached
Description: No in vivo coached quality control or fidelity monitoring
Study NCT02186873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo.
Study NCT02186873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive 2mg/kg of intravenous infusions of golimumab .
Study NCT04875962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0599
Description: Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.
Study NCT04875962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.
Study NCT01593410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg oral lenalidomide once daily on Days 1-21 every 28 days
Study NCT01593410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Cycle 1: 40 mg oral dexamethasone once daily on Days 8, 15, and 22. Cycle 2 and beyond: 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22
Study NCT04200560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic Handgrip Exercise
Description: 60 minute rhythmic handgrip exercise
Study NCT04200560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic Exercise Training
Description: Handgrip exercise training consisting of three 60-minute training sessions per week for eight weeks.
Study NCT00806975 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: KwikPen® and FlexPen®
Description: The treatment is changed to twice a day injection of the same unit of Novo Rapid 30 Mix injection FlexPen® or Humalog Mix 25 injection KwikPen®for 3 months, after which the final assessment is made.
Study NCT03587948 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetes mellitus
Description: Children and adolescents who is diagnosed with diabetes will be involved in case-group, and others will be involved in control-group.
Study NCT01007149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
Study NCT05544409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAKv1
Description: 1 hour sessions with the MAKv1 exoskeleton, thrice per week during 1 month
Study NCT01007149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in vials with solution for subcutaneous injection.
Study NCT00867685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2624
Description: Single dose of 40 mg AZD2624 liquid suspension, PO
Study NCT00867685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2624
Description: Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
Study NCT02841189 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: King Vision video Laryngoscope
Description: The King Vision video laryngoscope (Ambu) will be used for tracheal intubation.
Study NCT00810108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (Kaletra®) tablets
Description: The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).
Study NCT01286727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BB3
Description: intravenous drug
Study NCT02439294 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Without Obstructive Sleep Apnea (syndrome)
Study NCT02439294 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mild or moderate Obstructive Sleep Apnea (syndrome)
Study NCT02439294 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Severe Obstructive Sleep Apnea (syndrome)
Study NCT02439294 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP
Study NCT04355507 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chest computed tomography (CT)
Description: Chest computed tomography (CT) examination
Study NCT04355507 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reverse-transcription polymerase chain reaction (RT-PCR)
Description: Identification of viral RNA by reverse-transcription polymerase chain reaction
Study NCT00068328 — intervention group
Intervention type: PROCEDURE
Intervention: psychosocial assessment and care
Study NCT00068328 — intervention group
Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Study NCT02753933 — intervention group
Intervention type: OTHER
Intervention: MRI scan
Description: MRI head scan to be performed as the first Secondary Care contact.
Study NCT02753933 — intervention group
Intervention type: OTHER
Intervention: Neurology Appointment
Description: Outpatient appointment with Neurologist as the first Secondary Care contact
Study NCT04171154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectation
Description: writing task
Study NCT04171154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance
Description: listening